Québec City, Canada, November 27, 2018 – Feldan Therapeutics (hereafter “Feldan”), a preclinical biotechnology company specialized in the intracellular delivery of therapeutic proteins and peptides, has announced an investment of $1.3 million by Asahi Kasei Corporate Venture Capital (hereafter “AKCVC”). AKCVC is focused on investing in innovative global companies active in areas of strategic importance
We are proud partner of the CRISPR congress 2019 to be held in Québec City, June 17-20, 2019. This annual event provides an international forum for scientists and organizations interested in all aspects of CRISPR-Cas systems to present state of the art novel research and global trends in CRISPR biology. The topics covered range from
Congratulations to our CEO, François-Thomas Michaud, for his nomination in the category “Visionary Entrepreneur of the Year” for the Trophées Vision 2018, a distinction awarded by the Chambre de Commerce et d’Industrie de Québec. This price aims to honor an entrepreneur whom, by its vision, has distinguished himself in the past three years and continues
University of Iowa and Feldan Therapeutics awarded grant by the National Institutes of Health Quebec City, Canada, October 12, 2018 – David Guay, Research Director of Feldan Therapeutics (hereafter “Feldan”) announced that his collaborator, Dr. Paul McCray from the University of Iowa Carver College of Medicine (hereafter “UI”), was awarded a $2 million (USD) grant
QUÉBEC CITY, Sept. 18, 2018 /CNW Telbec/ – Feldan Therapeutics (hereafter “Feldan”) has announced the closing of a $12.5 millions Series A financing round led by GC (parent company of GC Pharma), with the participation of Stonebridge Ventures (South Korean-based investor), Anges Québec Capital, including members of Anges Québec, and existing investors. Feldan is focused on the development of
Seoul (South Korea) & Québec City (Canada) June 27, 2018 – GC LabCell (hereafter “GCLC”) and Feldan Therapeutics (hereafter “Feldan”) announced an agreement today granting GCLC exclusive rights to use the Feldan Shuttle platform in developing and manufacturing genetically engineered Natural Killer cells (“NK cells”) for human oncology. GCLC has an international expertise in the
QUEBEC CITY, May 29, 2018 – Feldan Therapeutics, Inc. announced today the issuance of a new patent related to the refinement of the Feldan Shuttle platform. This technology, a peptide-based delivery method which allows the introduction of foreign proteins, peptides or genome-editing nucleases inside cells, is applicable to the development of new therapies. The United States Patent
Feldan Therapeutics’ Research Director, Dr. David Guay, will be attending TIDES: Oligonucleotides and Peptide Therapeutics Conference next week, May 7-10th at Hynes Convention Center in Boston. Come to chat with him and attend to his presentation on May 07th, 3:15 pm to learn more about the development of the Feldan Shuttle technology. https://lifesciences.knect365.com/tides/speakers/david-guay-phd#
- 1
- 2